Celtic Pharma Holdings Appoints Dr. Andy Richards to its Advisory Board
|
 |
By Stephen Parker in Team News Published: Friday, 02 October 09 - 09:00 AM (GMT) Last Updated: Friday, 09 October 09 - 10:49 AM (GMT) |
| ||
Guernsey and London, 2nd October 2009 – Celtic Pharma Holdings Advisors LLP (“CPHA”), the advisor to the second Celtic Pharma fund, Celtic Pharma Holdings II LP (“CP2”), today announces it has appointed Dr. Andy Richards to its Advisory Board.
Dr. Richards is one of the UK’s best known and most successful biotechnology entrepreneurs with a strong track record of founding, investing in, and developing high growth biotechnology and healthcare companies. In the past ten years, he has played a key role in growing the value and generating significant returns for investors in a large number of UK biotechnology companies. Dr. Richards has also advised the UK Government’s Office of Life Sciences, which is led by the Minister for Science and Innovation Lord Drayson, and UK Trade & Investment on biotechnology issues.
He is currently Chairman of Altacor Ltd and Novacta Biosciences Ltd, and a non-executive director of Vectura Group plc, Summit Corp. plc, Biowisdom Ltd, Babraham Bioscience Technology Ltd , Cancer Research Technology Ltd (commercial arm of CR-UK), and Arecor Ltd. He is also founder member of the Cambridge Angels, a director of the UK Bioindustry Association (BIA) and a member of Biotechnology and Biological Sciences Research Council (BBSRC).
Dr. Richards spent his early career with ICI plc (now AstraZeneca plc) and with PA Technology. In 1992, he co-founded Chiroscience, one of Europe’s most successful biotech companies, and was business development director through to the merger in 1999 with Celltech (now UCB).
Dr. Richards has a track record in successful biotechnology exits having been a founder and director of Arakis Ltd, which was acquired by Sosei in 2005, Cambridge BioTechnology Ltd, acquired by Biovitrum in 2005, and PharmaKodex Ltd, acquired by Orexo in 2009.
Commenting on the appointment, John Mayo, Managing Partner of CP2 said: “Andy brings to our Advisory Board a wealth of experience in the identification and commercial development of innovative life science products and technologies which will complement the financial and pharmaceutical strengths of the Board. We look forward to working with him as we invest in further exciting, emerging companies to grow the value of CP2.”
Dr. Richards, said: “I am pleased to be joining the CP2 Advisory Board. I have been attracted by the group’s investment approach and the quality and experience of the other members of the Advisory Board. I look forward to working with the CP2 team to create the next wave of successful biotech and healthcare companies.”
A picture of Dr. Richards is available on request.
|
Please contact with enquiries:
|
|
|
Celtic Pharma Holdings Advisors LLP
|
John Mayo / Stephen Parker
|
|
|
Tel: +44 (20) 7291 5456
|
|
|
|
|
|
|
|
Citigate Dewe Rogerson
|
David Dible
Tel: +44 (0)20 7638 9571
|
NOTES TO EDITORS
About Celtic Pharma Holdings Advisors LLP
Celtic Pharma Holdings Advisors is a global private equity fund management partnership focused on the biotechnology and pharmaceutical industries. Our second fund, Celtic Pharma Holdings II LP, invests in companies which own proven technology platforms and early clinical development-stage pharmaceutical programmes and directs the management of these programmes through their development prior to sale at proof of concept with appropriate efficacy and safety data (usually at end of Phase II clinical trials).
CP2 has already attracted investment from sovereign wealth funds, pension funds and high net worth individuals from many countries and continues to raise further capital. For further information, please visit our website at www.celticpharmaholdings.com.
<-- Back
